Nucala Among Flurry Of New Respiratory Products On Indian Horizon

 
• By Anju Ghangurde

Novel asthma/COPD drugs, including GlaxoSmithKline’s biologic therapy Nucala, are on the horizon in India, set to expand treatment options in the competitive segment. But pricing is expected to be key in pushing uptake, and health care delivery in asthma/COPD in India remains rather sub-optimal, notwithstanding the interest around new launches.

Lungs
A SLEW OF NEW ASTHMA/COPD PRODUCTS ARE HEADED TO INDIA

More from Business

More from Scrip